Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

No Link Found Between Erectile Medications and HIV

16.11.2006
Erectile dysfunction (ED) medications known as Phosphodiesterase type 5 (PDE-5) inhibitors have been used by millions of men as safe and effective management options associated with high rates of patient and partner satisfaction.

Recent reports have appeared, however, that some individuals have misused this class of drug, combining them with narcotics such as methamphetamines. These reports further note that such individuals may be, in particular, at an increased risk for HIV. If such claims of a large and expanding use of PDE-5 inhibitors are correct, this would signify an important public health concern.

A comprehensive, multi-disciplinary conference funded by the National Institutes of Health sought to determine whether the drug class of PDE-5 inhibitors was contributing to an overall increase in HIV infection. The results of this conference appear in the latest issue of The Journal of Sexual Medicine.

Convincing evidence was not found to support the conclusion that PDE-5 inhibitor use is a risk factor for HIV infection. For the large majority of men, PDE-5 inhibitor use is conducted in a stable, committed partner relationship. Under such circumstances, the risk of HIV infection is relatively small. Clinicians and educators did emphasize, however, the importance of safe sex practices for those engaging in risky sexual relations.

“It’s impressive how responsible most men are who use ED drugs, and the benefits they and their partners achieve with them, but there is a potential for abuse that needs to be recognized,” says Raymond C. Rosen, PhD, lead author of the report. “I would not like to see Viagra, Cialis or Levitra being used as performance enhancement drugs—that’s not why these drugs were approved or why physicians prescribe them.”

Irwin Goldstein, Editor-in-Chief of The Journal of Sexual Medicine , noted that this paper is especially important to the field. “Health care providers should be reminded that individuals infected with HIV frequently have ED from their disease or from pharmacologic agents commonly used in its treatment. Positive clinical benefits have been reported in the HIV population when using PDE-5 inhibitor drugs as indicated.”

This study is published in the November issue of The Journal of Sexual Medicine. Media wishing to receive a PDF of this article please contact medicalnews@bos.blackwellpublishing.net

Raymond C. Rosen, PhD, is Chief Scientist at New England Research Institutes and professor of Psychiatry and Medicine at Robert Wood Johnson Medical School. He can be reached for questions at rrosen@neriscience.com

As the official publication of the International Society for Sexual Medicine, its affiliated regional societies (the Africa Gulf Society for Sexual Medicine, the Asia Pacific Society for Sexual Medicine, the European Society for Sexual Medicine, the Latin American Society for Sexual Medicine, and the Sexual Medicine Society of North America) and the International Society for the Study of Women’s Sexual Health, The Journal of Sexual Medicine is the authoritative, multidisciplinary source for sexual medicine. Publishing original research in both basic science and clinical investigations, The Journal of Sexual Medicine also features review articles, educational papers, editorials highlighting original research, and meeting information. Special topics include symposia proceedings and the official guidelines from the Second International Consultation on Sexual Dysfunctions in Men and Women. Edited by international experts, The Journal of Sexual Medicine disseminates the critical information that you need to know. For more information, please visit: http://www.blackwell-synergy.com/loi/jsm

Blackwell Publishing is the world’s leading society publisher, partnering with 665 academic and professional societies. Blackwell publishes over 800 journals and, to date, has published more than 6,000 books, across a wide range of academic, medical, and professional subjects. For more information, please visit: http://www.blackwellpublishing.com/

Sean Wagner | EurekAlert!
Further information:
http://www.blackwell-synergy.com/loi/jsm
http://www.blackwellpublishing.com/

More articles from Health and Medicine:

nachricht Fast-tracking T cell therapies with immune-mimicking biomaterials
16.01.2018 | Wyss Institute for Biologically Inspired Engineering at Harvard

nachricht Dengue takes low and slow approach to replication
12.01.2018 | Duke University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

White graphene makes ceramics multifunctional

16.01.2018 | Materials Sciences

Breaking bad metals with neutrons

16.01.2018 | Materials Sciences

ISFH-CalTeC is “designated test centre” for the confirmation of solar cell world records

16.01.2018 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>